Cargando…

Alteration of mitochondrial biogenesis promotes disease progression in multiple myeloma

Many cancers, including multiple myeloma (MM), retain more cytosolic iron to promote tumor cell growth and drug resistance. Higher cytosolic iron promotes oxidative damage due to its interaction with reactive oxygen species generated by mitochondria. The variation of mitochondrial biogenesis in diff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhan, Xin, Yu, Wenjie, Franqui-Machin, Reinaldo, Bates, Melissa L., Nadiminti, Kalyan, Cao, Huojun, Amendt, Brad A., Jethava, Yogesh, Frech, Ivana, Zhan, Fenghuang, Tricot, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762316/ https://www.ncbi.nlm.nih.gov/pubmed/29340048 http://dx.doi.org/10.18632/oncotarget.22740

Ejemplares similares

Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?
por: Franqui-Machin, Reinaldo, et al.
Publicado: (2015)

NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase
por: Gu, Zhimin, et al.
Publicado: (2017)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Role of NEK2A in Human Cancer and Its Therapeutic Potentials
por: Xia, Jiliang, et al.
Publicado: (2015)

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid
por: Xia, Jiliang, et al.
Publicado: (2017)

Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
por: Tomasson, Michael H., et al.
Publicado: (2018)

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
por: Hao, M, et al.
Publicado: (2017)

Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma
por: Ramani, Vishnu C., et al.
Publicado: (2015)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
por: Yang, Ye, et al.
Publicado: (2014)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

C-Reactive Protein Monitoring Predicts Neutropenic Fever Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
por: Kollu, Vidya, et al.
Publicado: (2018)

Extracellular vesicle expansion of PMIS‐miR‐210 expression inhibits colorectal tumour growth via apoptosis and an XIST/NME1 regulatory mechanism
por: Eliason, Steven, et al.
Publicado: (2022)

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
por: Kelly, Kevin R., et al.
Publicado: (2015)

Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression
por: Li, Can, et al.
Publicado: (2021)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
por: Gu, Chunyan, et al.
Publicado: (2018)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma
por: Han, Seong-Su, et al.
Publicado: (2015)

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance
por: Shi, Lei, et al.
Publicado: (2010)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Irx1 regulates dental outer enamel epithelial and lung alveolar type II epithelial differentiation
por: Yu, Wenjie, et al.
Publicado: (2017)

Dact2 Represses PITX2 Transcriptional Activation and Cell Proliferation through Wnt/beta-Catenin Signaling during Odontogenesis
por: Li, Xiao, et al.
Publicado: (2013)

Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients
por: Roy Choudhury, Samrat, et al.
Publicado: (2021)

Nek2 Is a Novel Regulator of B Cell Development and Immunological Response
por: Gu, Zhimin, et al.
Publicado: (2014)

Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells
por: Schibler, Jeanine, et al.
Publicado: (2016)

High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
por: Cheng, Yan, et al.
Publicado: (2023)

Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma
por: Salem, Kelley, et al.
Publicado: (2014)

Inhibition of Nek2 by Small Molecules Affects Proteasome Activity
por: Meng, Lingyao, et al.
Publicado: (2014)

The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis
por: Oliveira, Vanessa, et al.
Publicado: (2019)

Germline Risk Contribution to Genomic Instability in Multiple Myeloma
por: Janz, Siegfried, et al.
Publicado: (2019)

Intraocular bevacizumab in the treatment of choroidal metastases from breast cancer
por: Nadiminti, Kalyan, et al.
Publicado: (2016)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

A novel Iowa–Mayo validated composite risk assessment tool for allogeneic stem cell transplantation survival outcome prediction
por: Nadiminti, Kalyan, et al.
Publicado: (2021)

Management of multiple myeloma during COVID-19 pandemic
por: Jethava, YS, et al.
Publicado: (2020)

Mitochondrial biogenesis: An update
por: Popov, Lucia‐Doina
Publicado: (2020)

Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics
por: Roy Choudhury, Samrat, et al.
Publicado: (2023)

Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS
por: Guo, Wancheng, et al.
Publicado: (2023)

WDR26 and MTF2 are therapeutic targets in multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4stu19tu21qvi072hta7oqjl31